We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | 장 마감 후 (AMC) | $-0.21 | — | — | $21.45M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-11.42 | — | — | $21.77M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.29 | — | — | $69.58M |
Consensus PT $6 · 1 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 03. 16. | Benchmark | — | 의견 유지 | Speculative Buy → Speculative Buy | — | Benchmark: Speculative Buy |
| 2026. 03. 13. | Benchmark | — | 의견 유지 | Speculative Buy → Speculative Buy | — | Benchmark: Speculative Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.18 | — | — | $47.61M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,012,417 | $677.1M | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 114,117 | $555.75M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 MSN
Harvard Bioscience stock (US4169061052): steady trading as investors await next catalyst - AD HOC NEWS
Harvard Bioscience stock (US4169061052): steady trading as investors await next catalyst AD HOC NEWS
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
HBIO PE Ratio & Valuation, Is HBIO Overvalued Intellectia AI
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story AD HOC NEWS
Harvard Bioscience stock (US4169061052): restructuring progress and life science demand in focus - AD HOC NEWS
Harvard Bioscience stock (US4169061052): restructuring progress and life science demand in focus AD HOC NEWS
Harvard Bioscience Balances Margin Gains With Soft Sales - TipRanks
Harvard Bioscience Balances Margin Gains With Soft Sales TipRanks